Immunomodulatory Mechanisms of Fumaric Acid Esters in Neurological Disorders

Fumaric acid esters (FAEs), most notably dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF), have emerged as pivotal immunomodulatory agents in the management of multiple sclerosis (MS) and other neuroinflammatory conditions. These compounds exert a dual mode of action, combining antioxidant defence with direct modulation of immune cell function. Central to their efficacy is activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which enhances intracellular glutathione synthesis and mitigates oxidative stress in neurons and glial cells. Concurrently, FAEs attenuate pro-inflammatory signalling by inhibiting nuclear factor κB (NF-κB) activation and suppressing ubiquitin-mediated assembly of inflammatory signalling complexes. At the cellular level, FAEs skew T-lymphocyte subsets away from Th1/Th17 phenotypes towards regulatory and Th2 profiles, promote a shift of macrophages and microglia from M1 “classically activated” to M2 “alternatively activated” states, and reduce astrocytic release of neurotoxic mediators. These collective actions preserve neuronal integrity, restore synaptic homeostasis and alleviate demyelination. Growing evidence also highlights the gut as a critical site of DMF’s immunomodulatory onset, where early interactions with gut-associated lymphoid tissue contribute to its systemic benefits. As research advances, FAEs continue to offer a template for next-generation small molecules aimed at fine-tuning neuroimmune crosstalk in chronic neurological disorders.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Immunomodulatory Mechanisms of Fumaric Acid Esters in Neurological Disorders publication trend

The graph below shows the total number of articles in immunomodulatory mechanisms of fumaric acid esters in neurological disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Dimethyl fumarate (DMF): A small molecule immunomodulator used in oral therapy for multiple sclerosis; metabolises to monomethyl fumarate in vivo.

Nrf2 pathway: A cytoprotective signalling cascade led by nuclear factor erythroid 2-related factor 2 that upregulates antioxidant and detoxification genes.

Nuclear factor κB (NF-κB): A family of transcription factors that orchestrate expression of pro-inflammatory cytokines and adhesion molecules.

Regulatory type 1 T cells (Tr1): A subset of CD4⁺ T cells that secrete IL-10 and contribute to immunological tolerance.

M1/M2 macrophage polarisation: Functional states of macrophages; M1 denotes a pro-inflammatory phenotype, M2 an anti-inflammatory, tissue-repairing profile.

Experimental autoimmune encephalomyelitis (EAE): An animal model induced to mimic key immunopathological features of multiple sclerosis.

References

1. Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach. Archives of Toxicology (2024).
2. Dimethyl fumarate modulates the regulatory T cell response in the mesenteric lymph nodes of mice with experimental autoimmune encephalomyelitis. Frontiers in Immunology (2024).
3. Dimethyl Fumarate and Intestine: From Main Suspect to Potential Ally against Gut Disorders. International Journal of Molecular Sciences (2023).
4. Short-term exposure to dimethyl fumarate (DMF) inhibits LPS-induced IκBζ expression in macrophages. Frontiers in Pharmacology (2023).
5. Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Frontiers in Neurology (2018).
6. Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases. Frontiers in Immunology (2016).
7. Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling*. Journal of Biological Chemistry (2012).
8. Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation. Scientific Reports (2016).
9. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. International Journal of Molecular Sciences (2015).
10. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation. Journal of Neuroinflammation (2010).
11. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathologica (2015).
12. Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages. Journal of Neuroinflammation (2016).